| (Values in U.S. Thousands) | Jan, 2026 | Oct, 2025 | Apr, 2025 | Jan, 2025 | Oct, 2024 |
| Sales | 144 | 119 | 41 | 13 | 79 |
| Sales Growth | +21.48% | +186.40% | +220.88% | -83.66% | +146.10% |
| Net Income | -1,347 | -1,312 | -2,285 | -1,722 | -1,848 |
| Net Income Growth | -2.69% | +42.58% | -32.68% | +6.80% | +15.83% |
Kda Group Inc (KDA.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
KDA Group Inc provides technological and operational efficiency solutions for general and specialized health sectors through its technology platform, which includes electronic prescription platforms for Canada and the United States and Adherize and Medherize functionalities for pharmaceutical adherence and oncology-focused therapeutic monitoring. The company operates through two segments: Pharmaceutical Technology and Corporate.
Fiscal Year End Date: 07/31